Verastem, Inc.
(NASDAQ : VSTM)

( )
VSTM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.24%343.281.2%$589.37m
GILDGilead Sciences, Inc.
1.33%73.320.9%$534.10m
CELGCelgene Corporation
0.35%91.201.2%$502.04m
AMGNAmgen Inc.
-0.13%197.311.2%$470.98m
ILMNIllumina, Inc.
1.67%331.443.5%$390.25m
REGNRegeneron Pharmaceuticals, Inc.
1.00%378.562.6%$309.76m
VRTXVertex Pharmaceuticals Incorporated
0.65%176.861.9%$202.70m
ALXNAlexion Pharmaceuticals, Inc.
0.71%116.992.0%$186.49m
AAgilent Technologies, Inc.
0.75%64.951.5%$163.20m
SRPTSarepta Therapeutics, Inc.
1.18%129.1416.6%$139.77m
NKTRNektar Therapeutics
2.24%61.965.6%$128.47m
EXASExact Sciences Corporation
1.71%50.0525.3%$122.85m
BLUEBluebird Bio, Inc.
0.06%158.8014.6%$120.19m
BMRNBioMarin Pharmaceutical Inc.
0.72%99.744.4%$119.07m
INCYIncyte Corporation
0.83%69.622.5%$116.18m

Company Profile

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.